BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

LifeScience Antibody Drug Conjugates

APAC Antibody-Drug Conjugates Past Phase 2, and Who Owns Them Now

Seventeen of them have already been licensed outside their home market, and the companies that will sell most of them in the US and Europe are Merck, Astra...

November 04, 2026 | Analysis

Zhimeng Biopharma Completes Enrolment of 255 Patients in Pivotal ALS Phase II/III Trial in China

Shanghai Zhimeng Biopharma, Inc. ( "Zhimeng Biopharma") announced that its independently developed next-generation potassium channel opener, CB03-154,...

November 03, 2026 | News

Parse Biosciences and Nomic Bio Launch 100-Million-Cell Immune Dataset to Advance AI Drug Discovery

Parse Biosciences, a leading provider of scalable and publicly available single-cell sequencing technology, a subsidiary of QIAGEN, andNomic Bio, a leader ...

November 02, 2026 | News

TJ Biopharma Doses First Patient in Phase I Trial of CLDN6 × 4-1BB Bispecific Antibody for Advanced Solid Tumours

TJ-C64B is an internally developed CLDN6 × 4-1BB bispecific antibody for which TJ Biopharma retains global rights, and is among the leading pro...

October 28, 2026 | News

Menarini and Georgiamune Strike $1.1 Billion Licensing Deal to Advance Next-Generation Cancer Immunotherapy

GIM-621 is a preclinical-stage, first-in-class oral small molecule immunotherapy with potential application across multiple solid tumors. Georgiamune to...

October 27, 2026 | News

LOTTE Biologics and Alvotech Forge Long-Term Partnership to Expand Global Biosimilar Manufacturing Capacity

Collaboration covers multiple biosimilar products to be manufactured at LOTTE Biologics' Syracuse facility in New York Strategic long-term partnershi...

October 13, 2026 | News

12 APAC-Originated Programmes to Watch at ESMO 2026

When the ESMO Congress 2026 opens at IFEMA Madrid on Friday 23 October, the region that most European oncologists still think of as a fast follower will ho...

October 13, 2026 | News

OncoBayes’ OB-001 Shows Potential to Overcome ADC Resistance and Boost Brain Penetration of Cancer Drugs

OncoBayes, a privately held clinical-stage pharmaceutical company, announced the successful completion of preclinical work with OB-001, demonstrating the p...

October 08, 2026 | News

Phrontline Biopharma Doses First Patient in Global Phase I/II Trial of Bispecific ADC TJ102

Phrontline Biopharma, a clinical-stage biotechnology company developing next-generation antibody-drug conjugates (ADCs), announced that the first patient h...

October 02, 2026 | News

Earendil Labs, Genentech Ink $1.5B+ Deal to Develop AI-Driven Bispecific Antibodies

Earendil Labs, an AI-powered biotechnology company advancing next-generation biologics, today announced a research collaboration with Genentech, a member o...

September 25, 2026 | News

Sanyou Bio, NovoCodex Join Forces to Advance Next-Generation ADC Therapeutics

Sanyou Biopharmaceuticals Co., Ltd. ("Sanyou Bio") and NovoCodex Biopharmaceuticals Co., Ltd. ("NovoCodex") jointly announced that the two companies have f...

September 25, 2026 | News

Turbine, Daiichi Sankyo Expand Virtual Biology Collaboration to Accelerate ADC Discovery

Turbine, a leading virtual biology company, announced the expansion of its collaboration with Daiichi Sankyo following the successful completio...

September 25, 2026 | News

Tsingke Launches High-Throughput Validation Workflow for AI-Designed Proteins and Antibodies

Tsingke announced an integrated high-throughput validation workflow designed to help researchers experimentally evaluate large libraries of AI-designed pro...

September 24, 2026 | News

Solstice Oncology Launches with $225M Series A to Advance Harbour BioMed’s Porustobart

Porustobart, a second-generation Fc-enhanced CTLA-4 antibody, is being advanced across two clinical indications in the neoadjuvant setting, beginning...

September 11, 2026 | News

Stay Connected